Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioCorRx (BICX) Income from Continuing Operations (2016 - 2025)

BioCorRx's Income from Continuing Operations history spans 15 years, with the latest figure at 808505.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 46.56% year-over-year to 808505.0; the TTM value through Sep 2025 reached 4265178.0, up 13.91%, while the annual FY2024 figure was 5212102.0, 38.23% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 808505.0 at BioCorRx, up from 1377276.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 808505.0 in Q3 2025 and bottomed at 1584063.0 in Q1 2021.
  • The 5-year median for Income from Continuing Operations is 1167211.0 (2022), against an average of 1137242.47.
  • The largest annual shift saw Income from Continuing Operations tumbled 74.44% in 2024 before it surged 46.56% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 1203299.0 in 2021, then rose by 3.0% to 1167211.0 in 2022, then rose by 16.9% to 969943.0 in 2023, then decreased by 26.57% to 1227633.0 in 2024, then skyrocketed by 34.14% to 808505.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Income from Continuing Operations are 808505.0 (Q3 2025), 1377276.0 (Q2 2025), and 851764.0 (Q1 2025).